Sales & Marketing News | pharmaphorum

News

FDA clears nasal opioid reversal drug, lifting Indivior

The FDA has approved a new intranasal therapy for treating opioid overdose developed by Opiant Pharma, giving a boost to its new UK owner Indivior.

News

CD20 market heats up as FDA OKs AbbVie, Genmab bispecific

AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer

News

FDA clears Vyjuvek as first topical gene therapy

The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare genetic disease characterised by fragile skin that can split

News

Teva is eyeing $2.5bn in Austedo sales in 2027

The management of Israeli pharma group Teva has laid out its strategy for a return to growth after a challenging few years, with a greater emphasis on innovative medicines

News

New Veeva app connects medtech firms with KOLs

Veeva Systems has launched its latest cloud-based data application for the life sciences sector, aimed at clinical teams in the medical devices and diagnostics sector.

News

Cara, CSL Vifor’s CKD itching drug, backed for NHS use

Some patients in the UK with chronic kidney disease (CKD) who develop chronic itching – one of the most common and challenging side effects of dialysis – will soon be able

FDA clears nasal opioid reversal drug, lifting Indivior

CD20 market heats up as FDA OKs AbbVie, Genmab bispecific

FDA clears Vyjuvek as first topical gene therapy

Teva is eyeing $2.5bn in Austedo sales in 2027

New Veeva app connects medtech firms with KOLs

Cara, CSL Vifor’s CKD itching drug, backed for NHS use

UK patient first in world to get novel lung cancer vaccine

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks